<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395863</url>
  </required_header>
  <id_info>
    <org_study_id>MH 126</org_study_id>
    <nct_id>NCT00395863</nct_id>
  </id_info>
  <brief_title>Multihance at 3 Tesla in Brain Tumors</brief_title>
  <official_title>A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether Multihance is superior to Magnevist in terms
      of qualitative and quantitative assessment of unenhanced MRI and contrast-enhanced MRI for
      the visualization of brain disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Diagnostic Preference Between the Two Exams</measure>
    <time_frame>Postdose Images for MultiHance Exam and for Magnevist Exam Compared</time_frame>
    <description>Assessed by 3 blinded Readers for each of the 41 patients who had both MultiHance and Magnevist post dose MRI exam to assess whether the image with MultiHance was preferreed, both contrast agents were equal, or the image with Magnevist was preferred.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion Border Delineation</measure>
    <time_frame>Postdose Images for MultiHance Exam and for Magnevist Exam Compared</time_frame>
    <description>Assessed by 3 blinded Readers for each of the 41 patients who had both MultiHance and Magnevist post dose MRI exam to assess whether the image with MultiHance was preferreed, both contrast agents were equal, or the image with Magnevist was preferred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Contrast Enhancement Between the Two Exams</measure>
    <time_frame>Postdose Images for MultiHance Exam and for Magnevist Exam Compared</time_frame>
    <description>Assessed by 3 blinded Readers for each of the 41 patients who had both MultiHance and Magnevist post dose MRI exam to assess whether the image with MultiHance was preferreed, both contrast agents were equal, or the image with Magnevist was preferred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 1</measure>
    <time_frame>Predose and immediately postdose</time_frame>
    <description>Change from predose to postdose in lesion-to-brain ratio computed. Comparison of the differences in change were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 2</measure>
    <time_frame>Predose and immediately postdose</time_frame>
    <description>Change from predose to postdose in lesion-to-brain ratio computed. Comparison of the differences in change were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 3</measure>
    <time_frame>Predose and immediately postdose</time_frame>
    <description>Change from predose to postdose in lesion-to-brain ratio computed. Comparison of the differences in change were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 1</measure>
    <time_frame>Predose and immediately postdose</time_frame>
    <description>Change from predose to postdose in contrast-to-noise ratio computed. Comparison of the differences in change were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 2</measure>
    <time_frame>Predose and immediately postdose</time_frame>
    <description>Change from predose to postdose in contrast-to-noise ratio computed. Comparison of the differences in change were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 3</measure>
    <time_frame>Predose and immediately postdose</time_frame>
    <description>Change from predose to postdose in contrast-to-noise ratio computed. Comparison of the differences in change were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Contrast Enhancement of the Lesion - Reader 1</measure>
    <time_frame>Postdose</time_frame>
    <description>Quantitative parameter derived from signal intensity (SI) measurements. LCE ([SI of lesion (postdose)-SI of lesion (predose)]/Standard SI of lesion (predose)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Contrast Enhancement of the Lesion - Reader 2</measure>
    <time_frame>Postdose</time_frame>
    <description>Quantitative parameter derived from signal intensity (SI) measurements. LCE ([SI of lesion (postdose)-SI of lesion (predose)]/Standard SI of lesion (predose)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Contrast Enhancement of the Lesion - Reader 3</measure>
    <time_frame>Postdose</time_frame>
    <description>Quantitative parameter derived from signal intensity (SI) measurements. LCE ([SI of lesion (postdose)-SI of lesion (predose)]/Standard SI of lesion (predose)]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>MultiHance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 M MultiHance at a single injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnevist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 M Magnevist at a single injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multihance</intervention_name>
    <description>0.5 M at a single injection</description>
    <arm_group_label>MultiHance</arm_group_label>
    <other_name>gadobenate dimeglumine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 2 - Magnevist</intervention_name>
    <description>0.5 M Magnevist at a single dose injection</description>
    <arm_group_label>Magnevist</arm_group_label>
    <other_name>gadopentetate dimeglumine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Provide written informed consent

          -  Scheduled for MRI

          -  Confirmed or highly suspected to have brain tumor(s) and willing to undergo two MRI
             exams within 14 days

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Allergy to one or more of the ingredients in the products or hypersensitivity to any
             metals

          -  Congestive heart failure, class IV

          -  Previous stroke in the past year

          -  Received another contrast agent within 24 hours pre and post each exam

          -  Investigational product

          -  Contraindications to MRI

          -  Severe claustrophobia

          -  Surgery with 3 weeks prior

          -  Steroid therapy or radiosurgery between two exams
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianpaolo Priovano, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Bracco Diagnostics, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bracco Diagnostics, Inc.</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rumboldt Z, Rowley HA, Steinberg F, Maldjian JA, Ruscalleda J, Gustafsson L, Bastianello S. Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla. J Magn Reson Imaging. 2009 Apr;29(4):760-7. doi: 10.1002/jmri.21695.</citation>
    <PMID>19306364</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2006</study_first_submitted>
  <study_first_submitted_qc>November 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2006</study_first_posted>
  <results_first_submitted>March 30, 2009</results_first_submitted>
  <results_first_submitted_qc>June 8, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 31, 2009</results_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 47 patients were recruited from March 2007 through February 2008 at 8 clinical trial sites. from Feb/18/2008 to Feb/22/2008, an off-site assessment of the images was performed by 3 board-certified radiologists who were blinded to which contrast agent was used, any patient's clinical information &amp; any results from other imaging studies.</recruitment_details>
      <pre_assignment_details>47 patients enrolled (signed informed consent); 46 were randomized and dosed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MultiHance, Then Magnevist</title>
          <description>0.1 mmol/kg injection of each product</description>
        </group>
        <group group_id="P2">
          <title>Magnevist, Then MultiHance</title>
          <description>0.1 mmol/kg injection of each product</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patients did not complete both exams</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MultiHance, Then Magnevist</title>
          <description>0.1 mmol/kg injection of each product</description>
        </group>
        <group group_id="B2">
          <title>Magnevist, Then MultiHance</title>
          <description>0.1 mmol/kg injection of each product</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.79" spread="15.497"/>
                    <measurement group_id="B2" value="48.08" spread="16.064"/>
                    <measurement group_id="B3" value="49.43" spread="15.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Diagnostic Preference Between the Two Exams</title>
        <description>Assessed by 3 blinded Readers for each of the 41 patients who had both MultiHance and Magnevist post dose MRI exam to assess whether the image with MultiHance was preferreed, both contrast agents were equal, or the image with Magnevist was preferred.</description>
        <time_frame>Postdose Images for MultiHance Exam and for Magnevist Exam Compared</time_frame>
        <population>Include all ITT population. The number of units analyzed is the total number of technically adequate postdose images assessed by the reader from the total number of participants with both MultiHance- and Magnevist-enhanced images. Patient-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reader 1</title>
          </group>
          <group group_id="O2">
            <title>Reader 2</title>
          </group>
          <group group_id="O3">
            <title>Reader 3</title>
          </group>
        </group_list>
        <measure>
          <title>Global Diagnostic Preference Between the Two Exams</title>
          <description>Assessed by 3 blinded Readers for each of the 41 patients who had both MultiHance and Magnevist post dose MRI exam to assess whether the image with MultiHance was preferreed, both contrast agents were equal, or the image with Magnevist was preferred.</description>
          <population>Include all ITT population. The number of units analyzed is the total number of technically adequate postdose images assessed by the reader from the total number of participants with both MultiHance- and Magnevist-enhanced images. Patient-level analysis.</population>
          <units>Contrast-enhanced Images</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Contrast-enhanced Images</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MultiHance Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contrast Agents Equal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnevist Preffered</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Reader 1</p_value_desc>
            <method>wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Reader 2</p_value_desc>
            <method>wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Reader 3</p_value_desc>
            <method>wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Border Delineation</title>
        <description>Assessed by 3 blinded Readers for each of the 41 patients who had both MultiHance and Magnevist post dose MRI exam to assess whether the image with MultiHance was preferreed, both contrast agents were equal, or the image with Magnevist was preferred.</description>
        <time_frame>Postdose Images for MultiHance Exam and for Magnevist Exam Compared</time_frame>
        <population>Include all ITT population. The number of units analyzed is the total number of technically adequate postdose images assessed by the reader from the total number of participants with both MultiHance- and Magnevist-enhanced images. Patient-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reader 1</title>
          </group>
          <group group_id="O2">
            <title>Reader 2</title>
          </group>
          <group group_id="O3">
            <title>Reader 3</title>
          </group>
        </group_list>
        <measure>
          <title>Lesion Border Delineation</title>
          <description>Assessed by 3 blinded Readers for each of the 41 patients who had both MultiHance and Magnevist post dose MRI exam to assess whether the image with MultiHance was preferreed, both contrast agents were equal, or the image with Magnevist was preferred.</description>
          <population>Include all ITT population. The number of units analyzed is the total number of technically adequate postdose images assessed by the reader from the total number of participants with both MultiHance- and Magnevist-enhanced images. Patient-level analysis.</population>
          <units>Contrast-enhanced Images</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Contrast-enhanced Images</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MultiHance Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contrast Agents Equal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnevist Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Reader 1</p_value_desc>
            <method>wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Reader 2</p_value_desc>
            <method>wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Reader 3</p_value_desc>
            <method>wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Contrast Enhancement Between the Two Exams</title>
        <description>Assessed by 3 blinded Readers for each of the 41 patients who had both MultiHance and Magnevist post dose MRI exam to assess whether the image with MultiHance was preferreed, both contrast agents were equal, or the image with Magnevist was preferred.</description>
        <time_frame>Postdose Images for MultiHance Exam and for Magnevist Exam Compared</time_frame>
        <population>Include all ITT population. The number of units analyzed is the total number of technically adequate postdose images assessed by the reader from the total number of participants with both MultiHance- and Magnevist-enhanced images. Patient-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Reader 1</title>
          </group>
          <group group_id="O2">
            <title>Reader 2</title>
          </group>
          <group group_id="O3">
            <title>Reader 3</title>
          </group>
        </group_list>
        <measure>
          <title>Lesion Contrast Enhancement Between the Two Exams</title>
          <description>Assessed by 3 blinded Readers for each of the 41 patients who had both MultiHance and Magnevist post dose MRI exam to assess whether the image with MultiHance was preferreed, both contrast agents were equal, or the image with Magnevist was preferred.</description>
          <population>Include all ITT population. The number of units analyzed is the total number of technically adequate postdose images assessed by the reader from the total number of participants with both MultiHance- and Magnevist-enhanced images. Patient-level analysis.</population>
          <units>Contrast-enhanced Images</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Contrast-enhanced Images</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MultiHance Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contrast Agents Equal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnevist Preferred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Reader 1</p_value_desc>
            <method>wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Reader 2</p_value_desc>
            <method>wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Reader 3</p_value_desc>
            <method>wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 1</title>
        <description>Change from predose to postdose in lesion-to-brain ratio computed. Comparison of the differences in change were analyzed.</description>
        <time_frame>Predose and immediately postdose</time_frame>
        <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MultiHance</title>
            <description>0.1 mmol/kg injection</description>
          </group>
          <group group_id="O2">
            <title>Magnevist</title>
            <description>0.1 mmol/kg injection</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 1</title>
          <description>Change from predose to postdose in lesion-to-brain ratio computed. Comparison of the differences in change were analyzed.</description>
          <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
          <units>[ratio]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.17"/>
                    <measurement group_id="O2" value="0.85" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.30"/>
                    <measurement group_id="O2" value="1.31" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.33"/>
                    <measurement group_id="O2" value="0.46" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mean difference of MultiHance minus Magnevist for change from baseline</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.22</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 2</title>
        <description>Change from predose to postdose in lesion-to-brain ratio computed. Comparison of the differences in change were analyzed.</description>
        <time_frame>Predose and immediately postdose</time_frame>
        <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MultiHance</title>
            <description>0.1 mmol/kg injection</description>
          </group>
          <group group_id="O2">
            <title>Magnevist</title>
            <description>0.1 mmol/kg injection</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 2</title>
          <description>Change from predose to postdose in lesion-to-brain ratio computed. Comparison of the differences in change were analyzed.</description>
          <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
          <units>[ratio]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.18"/>
                    <measurement group_id="O2" value="0.87" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.28"/>
                    <measurement group_id="O2" value="1.36" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.36"/>
                    <measurement group_id="O2" value="0.49" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mean difference of Multihance minus Magnevist for change from baseline</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.30</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 3</title>
        <description>Change from predose to postdose in lesion-to-brain ratio computed. Comparison of the differences in change were analyzed.</description>
        <time_frame>Predose and immediately postdose</time_frame>
        <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MultiHance</title>
            <description>0.1 mmol/kg injection</description>
          </group>
          <group group_id="O2">
            <title>Magnevist</title>
            <description>0.1 mmol/kg injection</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion-to-brain Ratio (LBR) for Each Lesion - Reader 3</title>
          <description>Change from predose to postdose in lesion-to-brain ratio computed. Comparison of the differences in change were analyzed.</description>
          <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
          <units>[ratio]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.17"/>
                    <measurement group_id="O2" value="0.91" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.36"/>
                    <measurement group_id="O2" value="1.46" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.41"/>
                    <measurement group_id="O2" value="0.55" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mean difference of Multihance minus Magnevist for change from baseline</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.25</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 1</title>
        <description>Change from predose to postdose in contrast-to-noise ratio computed. Comparison of the differences in change were analyzed.</description>
        <time_frame>Predose and immediately postdose</time_frame>
        <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MultiHance</title>
            <description>0.1 mmol/kg injection</description>
          </group>
          <group group_id="O2">
            <title>Magnevist</title>
            <description>0.1 mmol/kg injection</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 1</title>
          <description>Change from predose to postdose in contrast-to-noise ratio computed. Comparison of the differences in change were analyzed.</description>
          <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
          <units>[ratio]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.81" spread="19.22"/>
                    <measurement group_id="O2" value="-11.70" spread="20.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.76" spread="66.88"/>
                    <measurement group_id="O2" value="26.87" spread="28.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.56" spread="71.57"/>
                    <measurement group_id="O2" value="38.57" spread="33.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0062</p_value>
            <p_value_desc>Mean difference of Multihance minus Magnevist for change from baseline</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>40.99</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>59.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>20.72</ci_lower_limit>
            <ci_upper_limit>61.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 2</title>
        <description>Change from predose to postdose in contrast-to-noise ratio computed. Comparison of the differences in change were analyzed.</description>
        <time_frame>Predose and immediately postdose</time_frame>
        <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MultiHance</title>
            <description>0.1 mmol/kg injection</description>
          </group>
          <group group_id="O2">
            <title>Magnevist</title>
            <description>0.1 mmol/kg injection</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 2</title>
          <description>Change from predose to postdose in contrast-to-noise ratio computed. Comparison of the differences in change were analyzed.</description>
          <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
          <units>[ratio]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.30" spread="19.11"/>
                    <measurement group_id="O2" value="-14.38" spread="18.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.96" spread="54.75"/>
                    <measurement group_id="O2" value="38.94" spread="40.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.26" spread="63.43"/>
                    <measurement group_id="O2" value="53.31" spread="52.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>Mean difference of Multihance minus Magnevist for change from baseline</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>30.95</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>48.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>16.57</ci_lower_limit>
            <ci_upper_limit>45.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 3</title>
        <description>Change from predose to postdose in contrast-to-noise ratio computed. Comparison of the differences in change were analyzed.</description>
        <time_frame>Predose and immediately postdose</time_frame>
        <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MultiHance</title>
            <description>0.1 mmol/kg injection</description>
          </group>
          <group group_id="O2">
            <title>Magnevist</title>
            <description>0.1 mmol/kg injection</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast-to-noise Ratio (CNR) for Each Lesion - Reader 3</title>
          <description>Change from predose to postdose in contrast-to-noise ratio computed. Comparison of the differences in change were analyzed.</description>
          <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
          <units>[ratio]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.75" spread="17.70"/>
                    <measurement group_id="O2" value="-6.47" spread="17.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.10" spread="42.92"/>
                    <measurement group_id="O2" value="42.34" spread="33.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.84" spread="47.60"/>
                    <measurement group_id="O2" value="48.81" spread="37.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>Mean difference of Multihance minus Magnevist for change from baseline</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>25.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>37.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>12.41</ci_lower_limit>
            <ci_upper_limit>37.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Contrast Enhancement of the Lesion - Reader 1</title>
        <description>Quantitative parameter derived from signal intensity (SI) measurements. LCE ([SI of lesion (postdose)-SI of lesion (predose)]/Standard SI of lesion (predose)]</description>
        <time_frame>Postdose</time_frame>
        <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MultiHance</title>
            <description>0.1 mmol/kg injection</description>
          </group>
          <group group_id="O2">
            <title>Magnevist</title>
            <description>0.1 mmol/kg injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Contrast Enhancement of the Lesion - Reader 1</title>
          <description>Quantitative parameter derived from signal intensity (SI) measurements. LCE ([SI of lesion (postdose)-SI of lesion (predose)]/Standard SI of lesion (predose)]</description>
          <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
          <units>[percent]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.15" spread="74.92"/>
                    <measurement group_id="O2" value="67.38" spread="52.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>Mean difference of Multihance minus Magnevist</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>32.77</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>48.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>14.28</ci_lower_limit>
            <ci_upper_limit>51.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Contrast Enhancement of the Lesion - Reader 2</title>
        <description>Quantitative parameter derived from signal intensity (SI) measurements. LCE ([SI of lesion (postdose)-SI of lesion (predose)]/Standard SI of lesion (predose)]</description>
        <time_frame>Postdose</time_frame>
        <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MultiHance</title>
            <description>0.1 mmol/kg injection</description>
          </group>
          <group group_id="O2">
            <title>Magnevist</title>
            <description>0.1 mmol/kg injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Contrast Enhancement of the Lesion - Reader 2</title>
          <description>Quantitative parameter derived from signal intensity (SI) measurements. LCE ([SI of lesion (postdose)-SI of lesion (predose)]/Standard SI of lesion (predose)]</description>
          <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
          <units>[percent]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.42" spread="84.97"/>
                    <measurement group_id="O2" value="72.81" spread="65.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>Mean difference of Multihance minus Magnevist</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>33.61</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>43.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>16.75</ci_lower_limit>
            <ci_upper_limit>50.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Contrast Enhancement of the Lesion - Reader 3</title>
        <description>Quantitative parameter derived from signal intensity (SI) measurements. LCE ([SI of lesion (postdose)-SI of lesion (predose)]/Standard SI of lesion (predose)]</description>
        <time_frame>Postdose</time_frame>
        <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MultiHance</title>
            <description>0.1 mmol/kg injection</description>
          </group>
          <group group_id="O2">
            <title>Magnevist</title>
            <description>0.1 mmol/kg injection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Contrast Enhancement of the Lesion - Reader 3</title>
          <description>Quantitative parameter derived from signal intensity (SI) measurements. LCE ([SI of lesion (postdose)-SI of lesion (predose)]/Standard SI of lesion (predose)]</description>
          <population>Include all ITT population. The number of units analyzed are the total number of lesions assessed by the reader from the total number of participants. Lesion-level analysis.</population>
          <units>[percent]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.85" spread="96.89"/>
                    <measurement group_id="O2" value="68.13" spread="60.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <p_value_desc>Mean difference of Multihance minus Magnevist</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>33.72</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>48.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>14.63</ci_lower_limit>
            <ci_upper_limit>52.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored from time of signed informed consent, &amp; within 24 hrs prior to administration of contrast agent (1st exam) until 24 hrs after administration of contrast agent. Repeated for 2nd exam.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MultiHance</title>
          <description>Adverse events experienced by patients occurred relative to the administration of MultiHance.</description>
        </group>
        <group group_id="E2">
          <title>Magnevist</title>
          <description>Adverse events experienced by patients occurred relative to the administration of Magnevist.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be presented during scientific symposia or published in a scientific journal only after review by Bracco in accordance with the guidelines set forth in the applicable publication or financial agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gianpaolo Pirovano</name_or_title>
      <organization>Executive Director, Head Corporate Medical Development</organization>
      <phone>609-514-2226</phone>
      <email>gianpaolo.pirovano@diag.bracco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

